I thought that over the next few days I would put up some posts about arthritis. My wife has settled with arthritis for years and not a lot has helped. There are of course a lot of pills on the market notably Vioxx and Celebrex (which my wife did take) the problems with these drugs is that the Cox-2 inhibitors have been linked to heart problems.

Arthritis

Arthritis is a general name for over 100 conditions and diseases that affect the joints of the bones. Many people with arthritis do not have any symptoms in the early stages, Later, there may be joint pain, swelling, and stiffness. The muscles surrounding the joint may be sore, too. Some common forms of arthritis are osteoarthritis, rheumatoid arthritis, fibromyalgia, tendinitis, and gout.

While not all of the causes of arthritis are known, several factors that may contribute to a person’s risk of developing the condition have been identified, including: Read the rest of this entry »

Looking to make a change and lose some weight? I have reviewed the top diet on the internet and you can go and read over 200 comments people have made about why this diet has worked well for them, as well as some of the problems.

Tags: arthritis, arthritis pain, bone ends, cartilage, Cox, fibromyalgia, gout, hips, inflammation, joint pain, joints, knees, muscles, osteoarthritis, pain, rheumatoid arthritis, sports injuries, tendinitis

Two years ago there were problems found with arthritis medications that contained Cox-2 inhibitors and both Vioxx and Celebrex were pulled off of the market. If you remember the problem was that users of these products had a higher inciednce of cariac problems compared to a control group that took a placebo. Now Merck, one of the largest drug manufacturers worldwide is trying to create a new drug called Arcoxia that also uses Cox-2 inhibitors as a painkiller to tackle arthritis pain.

Merck wants FDA approval to sell Arcoxia, also known as etoricoxib, to treat the signs and symptoms of osteoarthritis. The Whitehouse Station, N.J. company said its drug should be an option for the estimated 21 million Americans who suffer from osteoarthritis.

The FDA is at this point against this new drug although Merck says that the results are the same as an older Arthritis drug called Diclofenac which although older is apparently safe.

The reason that I bring this all up today is because it seems that after the initial hype and banning of Cox-2 based pain control there have not been many studies and it would be nice to see more info on the good or the bad of these Cox-2 based drugs

Tags: Arcoxia, arthritis, control group, Cox, Diclofenac, fda, Merck, New Jersey, osteoarthritis, pain, vioxx, Whitehouse Station

My wife has been taking high dosages of aspirin tow or three times a day for the last few months as she had some clots show up on her legs and the doctor, after having me give her injections to thin her blood, gave her this prescrition for a generic type of aspirin derivative that she is taking. As always I scoured the internet to find more information on taking aspirin and I have copied the following info from both Wikipedia and the FDA in case you have a simeilar interest. The wiki info is an outline on aspirin itself and the FDA info is a bunch of questions and answers about aspirin.

Aspirin or acetylsalicylic acid (acetosal) is a drug in the family of salicylates, often used as an analgesic (against minor pains and aches), antipyretic (against fever), and anti-inflammatory. It has also an anticoagulant (”blood-thinning”) effect and is used in long-term low-doses to prevent heart attacks.

Low-dose long-term aspirin irreversibly blocks the formation of thromboxane A2 in platelets, producing an inhibitory effect on platelet aggregation, and this blood-thinning property makes it useful for reducing the incidence of heart attacks. Aspirin produced for this purpose often comes in 75 or 81 mg dispersible tablets and is sometimes called “Junior aspirin”. High doses of aspirin are also given immediately after an acute heart attack. These doses may also inhibit the synthesis of prothrombin and may therefore produce a second and different anticoagulant effect.

Several hundred fatal overdoses of aspirin occur annually, but the vast majority of its uses are beneficial. Its primary undesirable side effects, especially in stronger doses, are gastrointestinal distress (including ulcers and stomach bleeding) and tinnitus. Another side effect, due to its anticoagulant properties, is increased bleeding in menstruating women. Because there appears to be a connection between aspirin and Reye’s syndrome, aspirin is no longer used to control flu-like symptoms in minors.[1]

Aspirin was the first discovered member of the class of drugs known as non-steroidal anti-inflammatory drugs (NSAIDs), not all of which are salicylates, though they all have similar effects and a similar action mechanism.
Read the rest of this entry »

Tags: A. Consumers, A. Patients, acetyl group, aches, allergy, angina pectoris, angioplasty, arthritis, Arthur Eichengr, Arthur Eichengrun, aspirin, aspirin products, Asthma, Bayer, body systems, British Columbia, bypass, Cerebral Ischemia, Charles Frederic Gerhardt, chemical, chemical structure, chemist, chest pain, chills, coronary artery disease, Cox, Department of Pharmaceutical Sciences, Derek W. Gilroy, diarrhea, Egypt, fda, fever, first discovered member, Friedrich Bayer & Co., Gerhardt, Germany, Glasgow, headaches, hearing loss, heart attack, heart attacks, Henri Leroux, Heyden Company, high blood pressure, Hoffmann, hydroxyl functional groups, ibuprofen, ISIS, John Robert Vane, juvenile rheumatoid arthritis, ketoprofen, kidney disease, London, Michigan, myocardial infarctions, osteoarthritis, pain, pains, pharmaceuticals industry, pharmacist, physician, pleurisy, Raffaele Piria, research assistant, researcher, Reye's syndrome, rheumatism, rheumatoid arthritis, Royal College of Surgeons in London, selective inhibitors, spondylarthropathies, stroke, Stroke Prevention, strokes, Sumeria, systemic lupus erythematosus, thrombus, tinnitus, transient ischemic attack, treatment of cardiovascular and cerebrovascular diseases, United Kingdom, United States, University of Strathclyde in Glasgow, unstable angina, Walter Sneader

Perhaps Vioxx and Celebrex and the Cox-2 inhibitors are not the culprit. There is an important report from England that is saying that using Ibuprofen as an arthritis pain killer will raise your heart attack risk as much as Vioxx or Celebrex.

High doses of older painkiller drugs may pose the same cardiac risk as newer medications such as
Vioxx and other cox-2 inhibitor drugs, according to a British study that looked at what is regarded as the best evidence from randomized, controlled trials.

Data from 138 such trials with 140,000 participants showed a 42 percent increased risk of serious blood vessel problems such as heart attack and stroke in those taking selective cox-2 inhibitors, the chemical class that includes Vioxx ,
Bextra and Celebrex. Cox-2 inhibitors belong to a broader class of pain relievers called nonsteroidal anti-inflammatory drugs (NSAIDs), which also include non-cox-2 medications such as ibuprofen, diclofenac, naproxen and aspirin.

And the study — which was funded by various U.K. public-sector medical groups — also found a similar increase in cardiac risk for other NSAIDs, said Dr. Colin Baigent, a reader in clinical epidemiology at the University of Oxford and an author of the report in the June 3 issue of the British Medical Journal.

Specifically, long-term use of high-dose (800 milligrams three times per day) ibuprofen was associated with a 51 percent higher risk for “vascular events” compared to placebo, while long-term use of high-dose (75 milligrams two times a day) diclofenac boosted the risk by 63 percent, the U.K. team reported. No such risk was seen with long-term use of naproxen (sold under the brand name Aleve).
Read the rest of this entry »

Tags: Aleve, arthritis, Author, Cataflam, chemical class, Cleveland Clinic, Colin Baigent, Cox, heart attack, heart disease, ibuprofen, interim chairman, Massage, Merck, Merck & Co., Motrin, pain, pain killing products, Steven Nissen, the British Medical Journal, United Kingdom, University of Oxford, vioxx

The blockbuster drug Vioxx was pulled from the market in the fall of 2004 after research showed that the painkiller doubled the risk of heart attack and stroke and that its use may have contributed to thousands of deaths in North America.
Now, a new Canadian study shows that the risk was even more dramatic because one in four of the heart attacks that occurred were within two weeks of the start of treatment.
“This demonstrates that cardiovascular risks from taking Vioxx may occur much earlier than previously believed,” said Linda Lévesque, an assistant professor in the department of community health and epidemiology at Queen’s University in Kingston.
At the same time, however, the research shows that additional risk virtually disappears within a month, meaning it is likely safe for long-term use.
The earlier data had suggested that the risk remained elevated for up to 18 months.
The research was published yesterday in the on-line edition of the Canadian Medical Association Journal.
Read the rest of this entry »

Tags: assistant professor in the department, Canada, Celebrex, Cox, digestive chemicals, director of the institute, heart attack, heart attacks, ibuprofen, Kingston, McGill University, Merck & Co. Inc., north America, on-line edition, Peter Liu, Quebec, Queen's University in Kingston, scientific director, stroke, the Canadian Medical Association Journal, United States, vioxx